Trials / Completed
CompletedNCT05770180
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
A Single-center, Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Booster Vaccination of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) in Healthy People Aged 18 Years and Older
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- WestVac Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
A single-center, randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of booster vaccination of Recombinant COVID-19 variant vaccine (Sf9 cell) in healthy people aged 18 years and older after completing 2 or 3 doses of novel coronavirus inactivated vaccine (Vero cells)
Detailed description
two dose level of Recombinant COVID-19 variant vaccine (Sf9 cell) compete with Recombinant COVID-19 vaccine (CHO cell) and Recombinant COVID-19 vaccine (Sf9 cell) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant COVID-19 variant vaccine (Sf9 cell) | WSK-V102 |
| BIOLOGICAL | Recombinant COVID-19 vaccine (CHO cell) | control 1 |
| BIOLOGICAL | Recombinant COVID-19 vaccine (Sf9 cell) | control 2 |
Timeline
- Start date
- 2023-03-30
- Primary completion
- 2023-07-30
- Completion
- 2024-04-09
- First posted
- 2023-03-15
- Last updated
- 2024-07-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05770180. Inclusion in this directory is not an endorsement.